Reduced von Willebrand Factor-Cleaving Protease Levels in Secondary Thrombotic Microangiopathies and Other Diseases

ABSTRACT

Thrombotic thrombocytopenic purpura (TTP) is a severe multisystem thrombotic microangiopathy (TMA). Significant advances have been made in understanding the pathogenesis of TTP since the discovery of ADAMTS-13 (a disintegrin and metalloproteinase with thrombospondin-1-like domains), the enzyme that regulates the size of von Willebrand factor (VWF) multimers. The inherited forms of TTP are mainly caused by a severe ADAMTS-13 deficiency, yet many aspects of the complex biological relationships between VWF-cleaving metalloproteinase and acquired TMA are still unclear. This latter issue will be critically addressed in this review article. In addition, the published literature evaluating plasma ADAMTS-13 levels in other pathologic conditions different from TMA will also be discussed.

ADAMTS-13 - von Willebrand factor - thrombotic microangiopathy

REFERENCES

• 1 Tsai H M. Current concepts in thrombotic thrombocytopenic purpura.  Annu Rev Med. 2006;  57 419-436
• 2 Franchini M, Zaffanello M, Veneri D. Advances in the pathogenesis, diagnosis and treatment of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.  Thromb Res. 2006;  118 177-184
• 3 Moake J L. Thrombotic microangiopathies.  N Engl J Med. 2002;  347 589-600
• 4 Levy G G, Motto D G, Ginsburg D. ADAMTS13 turns 3.  Blood. 2005;  106 11-17
• 5 Haspel R L, Jarolim P. The “cutting” edge: von Willebrand factor-cleaving protease activity in thrombotic microangiopathies.  Transfus Apher Sci. 2005;  32 177-184
• 6 George J N. Thrombotic thrombocytopenic purpura.  N Engl J Med. 2006;  354 1927-1935
• 7 Cal S, Obaya A J, Llamazares M, Garabaya C, Quesada V, Lopez-Otin C. Cloning, expression analysis, and structural characterization of seven novel human ADAMTSs, a family of metalloproteinases with disintegrin and thrombospondin-1 domains.  Gene. 2002;  283 49-62
• 8 Zheng X, Chung D, Takayama T K, Majerus E M, Sadler J E, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura.  J Biol Chem. 2001;  276 41059-41063
• 9 Gerritsen H E, Robles R, Lammle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease.  Blood. 2001;  98 1654-1661
• 10 Plaimauer B, Zimmermann K, Volkel D et al.. Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13).  Blood. 2002;  100 3626-3632
• 11 Ruoslahti E, Pierschbacher M D. Arg-Gly-Asp: a versatile cell recognition signal.  Cell. 1986;  44 517-518
• 12 Dong J F. Cleavage of ultra-large von Willebrand factor by ADAMTS-13 under flow conditions.  J Thromb Haemost. 2005;  3 1710-1716
• 13 Soejima K, Mimura N, Hirashima M et al.. A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease?.  J Biochem (Tokyo). 2001;  130 475-480
• 14 Levy G G, Nichols W C, Lian E C et al.. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.  Nature. 2001;  413 488-494
• 15 Turner N, Nolasco L, Tao Z, Dong J F, Moake J. Human endothelial cells synthesize and release ADAMTS-13.  J Thromb Haemost. 2006;  4 1396-1404
• 16 Furlan M, Robles R, Morselli B, Sandoz P, Lammle B. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura.  Thromb Haemost. 1999;  81 8-13
• 17 Liu L, Choi H, Bernardo A et al.. Platelet-derived VWF-cleaving metalloprotease ADAMTS-13.  J Thromb Haemost. 2005;  3 2536-2544
• 18 Dong J F, Moake J L, Nolasco L et al.. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions.  Blood. 2002;  100 4033-4039
• 19 Bernardo A, Ball C, Nolasco L, Moake J F, Dong J F. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow.  Blood. 2004;  104 100-106
• 20 Chauhan A K, Motto D G, Lamb C B et al.. Systemic antithrombotic effects of ADAMTS13.  J Exp Med. 2006;  203 767-776
• 21 Furlan M. Von Willebrand factor: molecular size and functional activity.  Ann Hematol. 1996;  72 341-348
• 22 Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lammle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura.  Blood. 1997;  89 3097-3103
• 23 Dent J A, Galbusera M, Ruggeri Z M. Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit.  J Clin Invest. 1991;  88 774-782
• 24 Chung D W, Fujikawa K. Processing of von Willebrand factor by ADAMTS-13.  Biochemistry. 2002;  41 11065-11070
• 25 Auton M, Cruz M A, Moake J. Conformational stability and domain unfolding of the von Willebrand factor A domains.  J Mol Biol. 2007;  366 986-1000
• 26 Lam J K, Chion C K, Zanardelli S, Lane D A, Crawley J T. Further characterization of ADAMTS-13 inactivation by thrombin.  J Thromb Haemost. 2007;  5 1010-1018
• 27 Crawley J T, Lam J K, Rance J B, Mollica L R, O'Donnell J S, Lane D A. Proteolytic inactivation of ADAMTS13 by thrombin and plasmin.  Blood. 2005;  105 1085-1093
• 28 Reiter R A, Knöbl P, Varadi K, Turecek P L. Changes in von Willebrand factor-cleaving protease (ADAMTS13) activity after infusion of desmopressin.  Blood. 2002;  101 946-948
• 29 Studt J-D, Hovinga J AK, Antoine G et al.. Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS-13 inhibitor: in vitro inhibition of ADAMTS-13 activity by hemoglobin.  Blood. 2005;  105 542-544
• 30 Mannucci P M, Canciani M T, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor.  Blood. 2001;  98 2730-2735
• 31 George J N, Li X, McMinn J R, Terrell D R, Vesely S K, Selby G B. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma.  Transfusion. 2004;  44 294-304
• 32 Fuge R, Bird J M, Fraser A et al.. The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation.  Br J Haematol. 2001;  113 58-64
• 33 Singh N, Gayowski T, Marino I R. Hemolytic uremic syndrome in solid-organ transplant recipients.  Transpl Int. 1996;  9 68-75
• 34 Kojouri K, George J N. Thrombotic microangiopathy following allogeneic hematopoietic stem cell transplantation.  Curr Opin Oncol. 2007;  19 148-154
• 35 Elliott M A, Nichols Jr W L, Plumhoff E A et al.. Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review.  Mayo Clin Proc. 2003;  78 421-430
• 36 van der Plas R M, Schiphorst M E, Huizinga E G et al.. von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura.  Blood. 1999;  93 3798-3802
• 37 Arai S, Allan C, Streiff M, Hutchins G M, Vogelsang G B, Tsai H M. Von Willebrand factor-cleaving protease activity and proteolysis of von Willebrand factor in bone marrow transplant-associated thrombotic microangiopathy.  Hematol J. 2001;  2 292-299
• 38 Peyvandi F, Siboni S M, Lambertenghi Deliliers D et al.. Prospective study on the behaviour of the metalloprotease ADAMTS13 and of von Willebrand factor after bone marrow transplantation.  Br J Haematol. 2006;  134 187-195
• 39 Vesely S K, George J N, Lammle B et al.. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients.  Blood. 2003;  102 60-68
• 40 Mal H, Veyradier A, Brugiere O et al.. Thrombotic microangiopathy with acquired deficiency in ADAMTS 13 activity in lung transplant recipients.  Transplantation. 2006;  81 1628-1632
• 41 Pham P T, Danovitch G M, Wilkinson A H et al.. Inhibitors of ADAMTS13: a potential factor in the cause of thrombotic microangiopathy in a renal allograft recipient.  Transplantation. 2002;  74 1077-1080
• 42 Adachi T, Matsushita T, Ichihashi R et al.. High titer of ADAMTS13 inhibitor associated with thrombotic microangiopathy of the gut and skeletal muscle after allogeneic hematopoietic stem cell transplantation.  Int J Hematol. 2006;  83 415-419
• 43 Park Y D, Yoshioka A, Kawa K et al.. Impaired activity of plasma von Willebrand factor-cleaving protease may predict the occurrence of hepatic veno-occlusive disease after stem cell transplantation.  Bone Marrow Transplant. 2002;  29 789-794
• 44 Ko S, Okano E, Kanehiro H et al.. Plasma ADAMTS13 activity may predict early adverse events in living donor liver transplantation: observations in 3 cases.  Liver Transpl. 2006;  12 859-869
• 45 Ulinski T, Charpentier A, Colombat M et al.. From humoral rejection to generalized thrombotic microangiopathy-role of acquired ADAMTS13 deficiency in a renal allograft recipient.  Am J Transplant. 2006;  6 3030-3036
• 46 Oleksowicz L, Bhagwati N, DeLeon-Fernandez M. Deficient activity of von Willebrand's factor-cleaving protease in patients with disseminated malignancies.  Cancer Res. 1999;  59 2244-2250
• 47 Mannucci P M, Karimi M, Mosalaei A, Canciani M T, Peyvandi F. Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 (von Willebrand factor cleaving protease).  Haematologica. 2003;  88 454-458
• 48 Koo B H, Oh D, Chung S Y et al.. Deficiency of von Willebrand factor-cleaving protease activity in the plasma of malignant patients.  Thromb Res. 2002;  105 471-476
• 49 Blot E, Decaudin D, Veyradier A, Bardier A, Zagame O L, Pouillart P. Cancer-related thrombotic microangiopathy secondary to von Willebrand factor-cleaving protease deficiency.  Thromb Res. 2002;  106 127-130
• 50 Fontana S, Gerritsen H E, Kremer Hovinga J, Furlan M, Lammle B. Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor-cleaving protease.  Br J Haematol. 2001;  113 100-102
• 51 Forman R B, Benkel S A, Novik Y, Tsai H M. Presence of ADAMTS13 activity in a patient with metastatic cancer and thrombotic microangiopathy.  Acta Haematol. 2003;  109 150-152
• 52 Böhm M, Gerlach R, Beecken W D, Scheuer T, Stier-Bruck I, Scharrer I. ADAMTS-13 activity in patients with brain and prostate tumors is mildly reduced, but not correlated to stage of malignancy and metastasis.  Thromb Res. 2003;  111 33-37
• 53 Hymes K B, Karpatkin S. Human immunodeficiency virus infection and thrombotic microangiopathy.  Semin Hematol. 1997;  34 117-125
• 54 Gunther K, Garizio D, Dhlamini B. The pathogenesis of HIV-related thrombotic thrombocytopenic purpura - is it different?.  ISBT Science Series. 2006;  1 246-250
• 55 Miller R F, Scully M, Cohen H et al.. Thrombotic thrombocytopenic purpura in HIV infected patients.  Int J STD AIDS. 2005;  16 538-542
• 56 Sahud M A, Claster S, Liu L, Ero M, Harris K, von Furlan M. Willebrand factor-cleaving protease inhibitor in a patient with human immunodeficiency syndrome-associated thrombotic thrombocytopenic purpura.  Br J Haematol. 2002;  116 909-911
• 57 Gunther K, Garizio D, Nesara P. ADAMTS13 activity and the presence of acquired inhibitors in human immunodeficiency virus-related thrombotic thrombocytopenic purpura.  Transfusion. 2007;  47 1710-1716
• 58 Veyradier A, Obert B, Houllier A, Meyer D, Girma J P. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathy: a study of 111 cases.  Blood. 2001;  98 1765-1772
• 59 Tsai H M, Chandler W L, Sarode R et al.. von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome.  Pediatr Res. 2001;  49 653-659
• 60 Amirlak I, Amirlak B. Hemolytic uremic syndrome: an overview.  Nephrologie. 2006;  11 213-218
• 61 Veyradier A, Obert B, Haddad E et al.. Severe deficiency of the specific von Willebrand factor-cleaving protease (ADAMTS 13) activity in a subgroup of children with atypical hemolytic uremic syndrome.  J Pediatr. 2003;  142 310-317
• 62 George J N, Vesely S K, James J A. Overlapping features of thrombotic thrombocytopenic purpura and systemic lupus erythematosus.  South Med J. 2007;  100 512-514
• 63 Gungor R, Furlan M, Lammle B, Kuhn F, Seger R A. Acquired deficiency of von Willebrand factor-cleaving protease in a patient suffering from acute systemic lupus erythematosus.  Rheumatology. 2001;  40 940-942
• 64 Matsuda J, Sanaka T, Gohchi K et al.. Occurrence of thrombotic thrombocytopenic purpura in a systemic lupus erythematosus patient with antiphospholipid antibodies in association with a decreased activity of von Willebrand factor-cleaving protease.  Lupus. 2002;  11 463-464
• 65 Mannucci P M, Vanoli M, Forza I, Canciani M T, Scorza R. Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis).  Haematologica. 2003;  88 914-918
• 66 Peyvandi F, Ferrari S, Lavoretano S, Canciani M T, Mannucci P M. von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura.  Br J Haematol. 2004;  127 433-439
• 67 Rick M E, Austin H, Leitman S F, Krizek D M, Aronson D L. Clinical usefulness of a functional assay for the von Willebrand factor cleaving protease (ADAMTS 13) and its inhibitor in a patient with thrombotic thrombocytopenic purpura.  Am J Hematol. 2004;  75 96-100
• 68 Starck M, Abedinpour F, Dendorfer U et al.. Acquired thrombotic thrombocytopenic purpura as the presenting symptom of systemic lupus erythematosus. Successful treatment with plasma exchange and immunosuppression-report of two cases.  Eur J Haematol. 2005;  75 436-440
• 69 Enami T, Suzuki T, Ito S et al.. Successful treatment of refractory thrombotic thrombocytopenic purpura with cyclosporine and corticosteroids in a patient with systemic lupus erythematosus and antibodies to ADAMTS13.  Intern Med. 2007;  46 1033-1037
• 70 Rieger M, Mannucci P M, Kremer Hovinga J A et al.. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases.  Blood. 2005;  106 1262-1267
• 71 Kobayashi T, Wada H, Kamikura Y et al.. Decreased ADAMTS13 activity in plasma from patients with thrombotic thrombocytopenic purpura.  Thromb Res. 2007;  119 447-452
• 72 Amoura Z, Costedoat-Chalumeau N, Veyradier A et al.. Thrombotic thrombocytopenic purpura with severe ADAMTS-13 deficiency in two patients with primary antiphospholipid syndrome.  Arthritis Rheum. 2004;  50 3260-3264
• 73 Hirata S, Okamoto H, Ohta S et al.. Deficient activity of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura in the setting of adult-onset Still's disease.  Rheumatology. 2006;  45 1046-1047
• 74 Sato T, Hanaoka R, Ohshima M et al.. Analyses of ADAMTS13 activity and its inhibitor in patients with thrombotic thrombocytopenic purpura secondary to connective tissue diseases: observations in a single hospital.  Clin Exp Rheumatol. 2006;  24 454-455
• 75 Liu F, Feys H B, Dong N, Zhao Y, Ruan C. Alteration of ADAMTS13 antigen levels in patients with idiopathic thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura and systemic lupus erythematosus.  Thromb Haemost. 2006;  95 749-750
• 76 Coppo P, Bengoufa D, Veyradier A et al.. Reseau d'Etude des Microangiopathies Thrombotiques de l'Adulte. Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement.  Medicine (Baltimore). 2004;  83 233-244
• 77 Zakarija A, Bennet C. Drug-induced thrombotic microangiopathy.  Semin Thromb Hemost. 2005;  31 681-690
• 78 Zheng X L, Kaufman R M, Goodnough L T, Sadler J E. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura.  Blood. 2004;  103 4043-4049
• 79 Nakazawa Y, Hashikura Y, Urata K et al.. Von Willebrand factor-cleaving protease activity in thrombotic microangiopathy after living donor liver transplantation: a case report.  Liver Transpl. 2003;  9 1328-1333
• 80 Bennett C L, Connors J M, Carwile J M et al.. Thrombotic thrombocytopenic purpura associated with clopidogrel.  N Engl J Med. 2000;  342 1773-1777
• 81 Zakarija A, Bandarenko N, Pandey D K et al.. Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration.  Stroke. 2004;  35 533-537
• 82 Tsai H M, Rice L, Sarode R, Chow T W, Moake J L. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura.  Ann Intern Med. 2000;  132 794-799
• 83 Bennett C L, Weinberg P D, Rozenberg-Ben-Dror K, Yarnold P R, Kwaan H C, Green D. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases.  Ann Intern Med. 1998;  128 541-544
• 84 Sugio Y, Okamura T, Shimoda K et al.. Ticlopidine-associated thrombotic thrombocytopenic purpura with an IgG-type inhibitor to von Willebrand factor-cleaving protease activity.  Int J Hematol. 2001;  74 347-351
• 85 Bennett C L, Kim B, Zakarija A SERF-TTP Research Group et al. Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project.  J Am Coll Cardiol. 2007;  50 1138-1143
• 86 Lesesne J B, Rothschild N, Erickson B et al.. Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry.  J Clin Oncol. 1989;  7 781-789
• 87 Cantrell J E, Phillips T M, Schein P S. Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy.  J Clin Oncol. 1985;  3 723-734
• 88 Nagaya S, Wada H, Oka K et al.. Hemostatic abnormalities and increased vascular endothelial cell markers in patients with red cell fragmentation syndrome induced by mitomycin C.  Am J Hematol. 1995;  50 237-243
• 89 Fung M C, Storniolo A M, Nguyen B, Arning M, Brookfield W, Vigil J. A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy.  Cancer. 1999;  85 2023-2032
• 90 Humphreys B D, Sharman J P, Henderson J M et al.. Gemcitabine-associated thrombotic microangiopathy.  Cancer. 2004;  100 2664-2670
• 91 Ravandi-Kashani F, Cortes J, Talpaz M, Kantarjian H M. Thrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia: coincidence or true side effect?.  Cancer. 1999;  85 2583-2588
• 92 Al-Zahrani H, Gupta V, Minden M D, Messner H A, Lipton J H. Vascular events associated with alpha interferon therapy.  Leuk Lymphoma. 2003;  44 471-475
• 93 Kojouri K, Vesely S K, George J N. Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: frequency, clinical features, and long-term outcomes.  Ann Intern Med. 2001;  135 1047-1051
• 94 Baliga R S, Wingo C S. Quinine induced HUS-TTP: an unusual presentation.  Am J Med Sci. 2003;  326 378-380
• 95 Gottschall J L, Elliot W, Lianos E, McFarland J G, Wolfmeyer K, Aster R H. Quinine-induced immune thrombocytopenia associated with hemolytic uremic syndrome: a new clinical entity.  Blood. 1991;  77 306-310
• 96 Gottschall J L, Neahring B, McFarland J G, Wu G G, Weitekamp L A, Aster R H. Quinine-induced immune thrombocytopenia with hemolytic uremic syndrome: clinical and serological findings in nine patients and review of literature.  Am J Hematol. 1994;  47 283-289
• 97 Mauro M, Zlatopolskiy A, Raife T J, Laurence J. Thienopyridine-linked thrombotic microangiopathy: association with endothelial cell apoptosis and activation of MAP kinase signalling cascades.  Br J Haematol. 2004;  124 200-210
• 98 Medina P J, Sipols J M, George J N. Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.  Curr Opin Hematol. 2001;  8 286-293
• 99 George J N. The association of pregnancy with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.  Curr Opin Hematol. 2003;  10 339-344
• 100 Hulstein J J, van Runnard Heimel P J, Franx A et al.. Acute activation of the endothelium results in increased levels of active von Willebrand factor in hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome.  J Thromb Haemost. 2006;  4 2569-2575
• 101 Lattuada A, Rossi E, Calzarossa C, Candolfi R, Mannucci P M. Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome.  Haematologica. 2003;  88 1029-1034
• 102 Lämmle B, Kremer Hovinga J A, Alberio L. Thrombotic thrombocytopenic purpura.  J Thromb Haemost. 2005;  3 1663-1675
• 103 Loof A H, van Vliet H H, Kappers-Klunne M C. Low activity of von Willebrand factor-cleaving protease is not restricted to patients suffering from thrombotic thrombocytopenic purpura.  Br J Haematol. 2001;  112 1087-1088
• 104 Bianchi V, Robles R, Alberio L, Furlan M, Lammle B. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura.  Blood. 2002;  100 710-713
• 105 Moore J C, Hayward C P, Warkentin T E, Kelton J G. Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders.  Blood. 2001;  98 1842-1846
• 106 Sosothikul D, Seksarn P, Pongsewalak S, Thisyakorn U, Lusher J. Activation of endothelial cells, coagulation and fibrinolysis in children with Dengue virus infection.  Thromb Haemost. 2007;  97 627-634
• 107 Matsuyama T, Uemura M, Ishikawa M et al.. Increased von Willebrand factor over decreased ADAMTS13 activity may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis.  Alcohol Clin Exp Res. 2007;  31(Suppl 1) S27-35
• 108 Feys H B, Canciani M T, Peyvandi F, Deckmyn H, Vanhoorelbeke K, Mannucci P M. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis.  Br J Haematol. 2007;  138 534-540
• 109 Mannucci P M, Capoferri C, Canciani M T. Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease.  Br J Haematol. 2004;  126 213-218
• 110 Ono T, Mimuro J, Madoiwa S et al.. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure.  Blood. 2006;  107 528-534
• 111 Nguyen T C, Liu A, Liu L et al.. Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis.  Haematologica. 2007;  92 121-124
• 112 Kremer Hovinga J A, Zeerleder S, Kessler P et al.. ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock.  J Thromb Haemost. 2007;  , In press
• 113 Martin K, Borgel D, Lerolle N et al.. Decreased ADAMTS-13 (A disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure.  Crit Care Med. 2007;  35 2375-2382
• 114 He S, Cao H, Magnusson C G et al.. Are increased levels of von Willebrand factor in chronic coronary heart disease caused by decrease in von Willebrand factor cleaving protease activity? A study by an immunoassay with antibody against intact bond 842Tyr-843Met of the von Willebrand factor protein.  Thromb Res. 2001;  103 241-248
• 115 Yoo G, Blomback M, Schenck-Gustafsson K, He S. Decreased levels of von Willebrand factor-cleaving protease in coronary heart disease and thrombotic thrombocytopenic purpura: study of a simplified method for assaying the enzyme activity based on ristocetin-induced platelet aggregation.  Br J Haematol. 2003;  121 123-129
• 116 Kaikita K, Soejima K, Matsukawa M, Nakagaki T, Ogawa H. Reduced von Willebrand factor-cleaving protease (ADAMTS13) activity in acute myocardial infarction.  J Thromb Haemost. 2006;  4 2490-2493
• 117 Chion C K, Doggen C J, Crawley J T, Lane D A, Rosendaal F R. ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men.  Blood. 2007;  109 1998-2000
• 118 Matsukawa M, Kaikita K, Soejima K et al.. Serial changes in von Willebrand factor-cleaving protease (ADAMTS13) and prognosis after acute myocardial infarction.  Am J Cardiol. 2007;  100 758-763
• 119 Ruan C, Dai L, Su J, Wang Z, Ruan C. The frequency of P475S polymorphism in von Willebrand factor-cleaving protease in the Chinese population and its relevance to arterial thrombotic disorders.  Thromb Haemost. 2004;  91 1257-1258
• 120 Bongers T N, de Maat M P, van Goor M L et al.. High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability.  Stroke. 2006;  37 2672-2677
• 121 Mannucci P M, Parolari A, Canciani M T, Alemanni F, Camera M. Opposite changes of ADAMTS-13 and von Willebrand factor after cardiac surgery.  J Thromb Haemost. 2005;  3 397-399
• 122 Lo B, Nierich A P, Kalkman C J, Fijnheer R. Relatively increased von Willebrand factor activity after off-pump coronary artery bypass graft surgery.  Thromb Haemost. 2007;  97 21-26
• 123 Lian E C. Pathogenesis of thrombotic thrombocytopenic purpura: ADAMTS13 deficiency and beyond.  Semin Thromb Hemost. 2005;  31 625-632